AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 102 min read$JNJ

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)

Analysts from UBS, Bank of America, and H.C. Wainwright provided ratings and price targets for Johnson & Johnson (JNJ), United Therapeutics (UTHR), and Ionis Pharmaceuticals (IONS). JNJ has a Strong Buy consensus with a $289.71 target, UTHR has a Moderate Buy consensus with a $643.00 target, and IONS has a Strong Buy consensus with an $84.00 target.

Original reporting
theglobeandmail.com
Published Oct 10, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 3:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$JNJBullishLow
01

Why it matters

The new ratings introduce fresh price targets that could influence short‑term trading decisions, especially for Ionis and Johnson & Johnson.

02

Market read

Analyst rating updates provide modest trading signals for the three highlighted stocks.

03

What to watch

Potential macro headwinds or upcoming earnings could offset the rating impact.

Relevance 6/10Novelty 5/10Timing: today

Background

The article aggregates fresh analyst rating updates for three healthcare companies, providing price targets and consensus ratings.

Company-level read

Ticker impact

$JNJBullishMedium confidence
Context

UBS analyst Michael Yee maintained a Buy rating and set a $320 price target for Johnson & Johnson, a new rating released today.

Expected impact

likely upward pressure as investors price in the $320 target

Evidence & confidence

Analyst upgrade and a sizable upside target provide fresh bullish impetus.

$UTHRNeutralLow confidence
Context

Bank of America analyst Jason Gerberry reiterated a Hold rating with a $559 price target, released today.

Expected impact

limited movement, slight upside potential from the $559 target

Evidence & confidence

Hold stance signals no strong directional bias.

$IONSBullishMedium confidence
Context

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and set a $100 price target for Ionis Pharmaceuticals, released today.

Expected impact

upward pressure as market digests the 92% upside implied by the $100 target

Evidence & confidence

Significant upside from a new target may attract buying interest.

Market effects

Sector

Analyst upgrades may lift sentiment across the broader healthcare sector.

Regional

U.S. healthcare stocks could see modest gains.

Global

Limited to investors tracking large-cap healthcare names.

Counterpoint

What could challenge this read

Some investors may view the upgrades as already priced in and remain cautious.

Key entities

  • Analyst
    Michael Yee

    UBS analyst covering healthcare.

  • Analyst
    Jason Gerberry

    Bank of America Securities analyst covering healthcare.

  • Analyst
    Mitchell Kapoor

    H.C. Wainwright analyst covering healthcare.

Read at source← All news

Related articles

OCT 18
$UNHMed

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.

tradingview.com3 min
OCT 17
$JNJHighAI 8/10

Johnson & Johnson (JNJ) Shares Fall 5.73% Despite Strong Q3 Earn

Johnson & Johnson (JNJ) shares fell 5.73% despite Q3 earnings beating expectations. The company reported adjusted EPS of $2.59 and revenues of $25.40 billion, a 5.9% YoY increase. JNJ raised full-year guidance but faced pressure from a $5.5 billion talc charge and slowing growth in key segments. The stock has a 2.04% dividend yield and a GF Score of 83/100, but is trading 31.4% above its intrinsic value.

gurufocus.com3 min
OCT 17
$JNJHighAI 8/10

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.

Johnson & Johnson (JNJ) reported Q3 revenue of $25.9B and EPS of $2.59, beating estimates, but shares fell 6% due to weak medical device sales. The company raised its 2026 sales and earnings guidance. JNJ's medical tech division, about 1/3 of total sales, underperformed, with CEO hinting at a potential spinoff of its orthopedics business. Despite this, JNJ's oncology business grew 16% YoY, driven by key drugs like Darzalex, Rybrevant, and Tecvayli.

finance.yahoo.com3 min
OCT 16
$JNJMed

Johnson & Johnson Announces CHMP Recommendation For Approval Of TALVEY Plus Daratumumab In Earlier Line Treatment Of Relapsed/Refractory Multiple Myeloma

Johnson & Johnson reported that the CHMP recommended approval for TALVEY (talquetamab) plus daratumumab for relapsed/refractory multiple myeloma. The MonumenTAL-3 study showed significant improvements in progression-free and overall survival for talquetamab combinations compared to standard treatment. Key secondary endpoints also showed statistically significant improvements, with manageable safety profiles.

marketscreener.com2 min
OCT 16
$IONSHighAI 8/10

FDA Drug Approvals In September 2026

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.

rttnews.com3 min